Iconovo receives approval of additional patent for ICOres® in the EU

Iconovo AB (publ), that develops complete inhalation products for a global market, today announced that the European Patent Office (EPO) has provided a Notice of Allowance regarding an additional patent application for the inhaler platform ICOres. ICOres is currently being used in several of Iconovo’s customer projects and this additional patent will bring a longer and improved protection period for customers launching in the future.

First patent granted in Japan for Iconovo’s ICOone

Iconovo AB (publ), that develops complete inhalation products for a global market, today announces that the Japanese patent authority JPO has submitted a Notice of Allowance regarding Iconovo's patent application for the inhaler platform ICOone. The patent describes the single-dose inhaler which is currently part of three innovative partner projects including the administration of oxytocin and covid-19 vaccine. Iconovo already has a well-established patent portfolio for ICOone in Sweden, Europe (EPO), USA, China, and India.

Iconovo updates its long-term financial targets – expects strong revenue growth with a high margin

Iconovo AB (publ), that develops complete inhalation products for a global market, today announces its five-year targets for the company. The company expects to reach sales of SEK 250 million in 2027. The target for the operating profit in the same year is SEK 125 million, resulting in an operating margin of 50 percent. The company expects about one third of the revenue stream to come from Iconovo's own pharmaceutical sales in the Nordic region through its subsidiary Iconovo Pharma. Iconovo's future prospects and financial targets was described in more detail at a Capital Markets Day in Swedish and the presentations will soon be available on the company´s website.

Abbreviated interim report 1 January – 31 March 2022

Significant successes for ICOres and ICOone

Iconovo and Galenica enters a strategic collaboration for the development of new inhalation products

Iconovo AB (publ), that develops complete inhalation products for a global market, has entered into a strategic collaboration with Galenica AB – a company specializing in the development and manufacture of pharmaceuticals for clinical studies. The main purpose of the collaboration is to facilitate the manufacturing of clinical trial material for companies developing new drugs for Iconovo's innovative single dose inhaler ICOone.

Iconovo extends collaboration with ISR with an agreement worth 13.6 million Swedish kronor (SEK)

Iconovo AB expands its collaboration with immunotherapy company Immune System Regulation (ISR) that accelerates the development of an inhaled vaccine for covid-19. The contract value of the collaboration between ISR and Iconovo increases by 13.6 million SEK. Iconovo is also entitled to low, single-digit royalty on the sale of the finalized product.

Abbreviated year-end report 1 January – 31 December 2021

Significant progress in Iconovo’s three strategic business areas

Iconovo announces completion of comparative clinical study of ICOres budesonide/formoterol and Symbicort Turbuhaler

Iconovo AB (publ), a company developing complete inhalation products for a global market, today announces that a clinical pilot pharmacokinetic study, comparing the pharmacokinetic profile of ICOres budesonide/formoterol and Symbicort® Turbuhaler®, has been successfully concluded. The study, which was carried out by Amneal Pharmaceuticals, has provided valuable data that supports continued development of ICOres budesonide/formoterol as a potential generic substitution of Symbicort® Turbuhaler® for the management of asthma and COPD.

Iconovo establishes Iconovo Pharma AB as a subsidiary for pharmaceutical sales in the Nordic countries

Iconovo AB (publ), that develops complete inhalation products for a global market, has registered the subsidiary Iconovo Pharma AB with the Swedish Companies Registration Office. This is part of the previously communicated strategy to establish an infrastructure for in-house pharmaceutical sales in the Nordic market. Iconovo's goal is to reach sales revenues of SEK 200 million by 2026, of which approximately one third is estimated to come from Iconovo Pharma.

Iconovo and TOA sign agreement for development of a generic product

Iconovo AB (publ), that develops complete inhalation products for a global market, and TOA Pharmaceutical Co., Ltd, which develops generic products for the Japanese market announced today that they have signed a feasibility agreement to use an inhaler from Iconovo for a generic product development. The feasibility agreement has a value of EUR 202.000 to be paid over the coming 12 months.